Insulet focuses on its long-term strategy, shares in the S&P 500 medical devices peer group

Insulet leans on its diabetes technology franchise and recurring revenue model as investors compare the S&P 500 medtech stock to peers such as Dexcom and Abbott Laboratories.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:21.

Insulet (US45784P1012) continues to build out its diabetes-care franchise on the NASDAQ, where the shares trade as PODD and sit in the S&P 500 medical devices cohort alongside Dexcom and Abbott Laboratories. The focus for long-term investors is on the firm’s pump-based insulin delivery strategy and recurring revenue economics.

How Insulet earns its money

Insulet generates the bulk of its revenue from its Omnipod family of tubeless insulin pumps and the associated disposable pods, creating a high share of recurring sales as patients replace pods on a regular schedule. According to the company’s latest annual filings, consumables tied to the Omnipod ecosystem account for a significant majority of total revenue, supporting predictable cash flows over multi-year horizons.

Management aims to increase penetration in Type 1 and insulin-requiring Type 2 diabetes, particularly in the United States and Europe, and highlights that pump adoption still has room to grow against traditional multiple daily injections, leaving a sizeable addressable market for the Insulet business model. Sector analysts covering medtech compare Insulet’s growth runway to that of peers such as Dexcom in continuous glucose monitoring and Abbott in broader diabetes-care solutions, framing the company as a focused insulin-delivery play within the wider S&P 500 healthcare segment.

Long-term strategy and competitive positioning

Insulet’s long-term strategy centers on expanding the installed base of Omnipod users and deepening integration with diabetes-management software, including smartphone apps and connectivity to glucose-monitoring systems. This integration is designed to improve treatment adherence and patient experience, which in turn supports pod usage and recurring revenue.

In the competitive landscape, Insulet faces established insulin pump players such as Medtronic and Tandem Diabetes Care, while Dexcom and Abbott remain key partners and competitors in glucose monitoring. Market commentary from US medtech analysts points to sustained demand for diabetes technology solutions as a long-term tailwind, even if individual quarterly growth rates can be volatile.

The product behind the stock

Insulet’s flagship product is the Omnipod insulin management system, a small, wearable, tubeless insulin pump that adheres to the skin and delivers continuous subcutaneous insulin according to preprogrammed settings. The system is designed to replace multiple daily injections, offering discretion and ease of use for people living with diabetes.

Where the shares trade today

The Insulet shares (US45784P1012) last closed on the NASDAQ on 2026-06-26 at 158.25 US dollars, according to MarketBeat data.

Key data on the Insulet shares

• Company: Insulet Corporation
• ISIN: US45784P1012
• WKN: A0J3H9
• Ticker: PODD
• Trading venue: NASDAQ
• Price (as of 2026-06-26, 16:00): 158.25 USD
• Market cap: 10.50 billion USD (as of 2026-06-26)
• Sector / industry: Health Care / Medical Devices
• Index membership: S&P 500
• Next earnings date: 2026-08-06

This text is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Historical data and analyst assessments are no guarantee for future performance of the Insulet shares.